Heparin resistance in severe thermal injury: a prospective cohort study

Abstract

Background: Low molecular-weight heparin (LMWH) is routinely administered to burn patients for thromboprophylaxis. Some studies have reported heparin resistance, yet the mechanism(s) and prevalence have not been systematically studied. We hypothesized that nucleosomes, composed of histone structures with associated DNA released from injured tissue and activated immune cells in the form of neutrophil extracellular traps (NETs or NETosis), neutralize LMWH resulting in suboptimal anticoagulation, assessed by reduction in anti-factor Xa activity. Methods: Blood was sampled from >15% total body surface area (TBSA) burn patients receiving LMWH on days 5, 10 and 14. Peak anti-factor Xa (AFXa) activity, anti-thrombin (ATIII) activity, cell-free DNA (cfDNA) levels and nucleosome levels were measured. Mixed effects regression was adjusted for multiple confounders, including injury severity and ATIII activity, and was used to test the association between nucleosomes and AFXa. Results: A total of 30 patients with severe burns were included. Mean TBSA 43% (SD 17). Twenty-three (77%) patients were affected by heparin resistance (defined by AFXa activity <0.2 IU/mL). Mean peak AFXa activity across samples was 0.18 IU/mL (SD 0.11). Mean ATIII was 81.9% activity (SD 20.4). Samples taken at higher LWMH doses were found to have significantly increased AFXa activity, though the effect was not observed at all doses, at 8000 IU no samples were heparin resistant. Nucleosome levels were negatively correlated with AFXa (r = −0.29, p = 0.050) consistent with the hypothesis. The final model, with peak AFXa as the response variable, was adjusted for nucleosome levels (p = 0.0453), ATIII activity (p = 0.0053), LMWH dose pre-sample (p = 0.0049), drug given (enoxaparin or tinzaparin) (p = 0.03), and other confounders including severity of injury, age, gender, time point of sample. Conclusions: Heparin resistance is a prevalent issue in severe burns. Nucleosome levels were increased post-burn, and showed an inverse association with AFXa consistent with the hypothesis that they may interfere with the anticoagulant effect of heparin in vivo and contribute to heparin resistance. Accurate monitoring of AFXa activity with appropriate therapy escalation plans are recommended with dose adjustment following severe burn injury.

Keywords

Burn / Heparin resistance / Low molecular-weight heparin / Nucleosomes / Neutrophil extracellular traps / Factor-Xa / Thrombosis / Enoxaparin / NETosis

References

[1] Huzar TF, Martinez E, Love J, George TC, Shah J, Baer L, et al. Admission rapid thrombelastography (rTEG^®) values predict resuscitation volumes and patient outcomes after thermal injury. J Burn Care Res. 2018; 39: 345-52.

[2] Van Haren RM, Thorson CM, Valle EJ, Busko AM, Guarch GA, Andrews DM, et al. Hypercoagulability after burn injury. J Trauma Acute Care Surg. 2013; 75: 37-43.

[3] Wiegele M, Schaden E, Koch S, Bauer D, Krall C, Adelmann D. Thrombin generation in patients with severe thermal injury. Burns. 2019; 45: 54-62.

[4] Tejiram S, Brummel-Ziedins KE, Orfeo T, Mete M, Desale S, Hamilton BN, et al. In-depth analysis of clotting dynamics in burn patients. J Surg Res. 2016; 202(2): 341-51.

[5] Østerud B, Bjørklid E. Blood-borne tissue factor (including microparticles). Madame Curie Biosci Database. 2013.

[6] Lippi G, Ippolito L, Cervellin G. Disseminated intravascular coagulation in burn injury. Semin Thromb Hemost. 2010; 36: 429- 36.

[7] Cato LD, Wearn CM, Bishop JRB, Stone MJ, Harrison P, Moiemen N. Platelet count: a predictor of sepsis and mortality in severe burns. Burns. 2017; 44: 288-97.

[8] Dinsdale RJ, Devi A, Hampson P, Wearn CM, Bamford AL, Hazeldine J, et al. Changes in novel haematological parameters following thermal injury: a prospective observational cohort study. Sci Rep. 2017; 7: 3211.

[9] Marck RE, van der Bijl I, Korsten H, Lorinser J, de Korte D, Middelkoop E. Activation, function and content of platelets in burn patients. Platelets. 2018; 1-7.

[10] Lupia E, Bosco O, Mariano F, Dondi AE, Goffi A, Spatola T, et al. Elevated thrombopoietin in plasma of burned patients without and with sepsis enhances platelet activation. J Thromb Haemost. 2009; 7: 1000-8.

[11] Gould TJ, Vu TT, Swystun LL, Dwivedi DJ, Mai SHC, Weitz JI, et al. Neutrophil extracellular traps promote thrombin generation through platelet-dependent and platelet-independent mechanisms. Arterioscler Thromb Vasc Biol. 2014; 34: 1977-84.

[12] Pfeiler S, Stark K, Massberg S, Engelmann B. Propagation of thrombosis by neutrophils and extracellular nucleosome networks. Haematologica. 2016; 102: 206-13.

[13] Fuchs TA, Brill A, Duerschmied D, Schatzberg D, Monestier M, Myers DD, et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A. 2010; 107: 15880-5.

[14] Hampson P, Dinsdale R, Wearn C, Bamford A, Bishop JB, Hazeldine J, et al. Neutrophil dysfunction, immature granulocytes, and cell-free DNA are early biomarkers of sepsis in burn-injured patients: a prospective observational cohort study. Ann Surg. 2016; 265: 1241-9.

[15] Pannucci C, Osborne N, Wahl W. Venous thromboembolism in thermally injured patients: analysis of the National Burn Repository. J Burn Care Res. 2012; 32: 6-12.

[16] Faucher LD, Conlon KM. Practice guidelines for deep venous thrombosis prophylaxis in burns. J Burn Care Res. 2007; 28: 661-3.

[17] Li Q, Ba T, Wang LF, Chen Q, Li F, Xue Y. Stratification of venous thromboembolism risk in burn patients by Caprini score. Burns. 2019; 45: 140-5.

[18] Sikora S, Papp A. Venous thromboembolism in burn patients is not prevented by chemoprophylaxis. Burns. 2017; 43: 1330-4.

[19] Levine MN, Hirsh J, Gent M, Turpie AG, Cruickshank M, Weitz J, et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med. 1994; 154: 49.

[20] Uprichard J, Manning RA, Laffan MA. Monitoring heparin anticoagulation in the acute phase response. Br J Haematol. 2010; 149: 613-9.

[21] Mitsuguro M, Okamoto A, Shironouchi Y, Sano M, Miyata S, Neki R, et al. Effects of factor VIII levels on the APTT and anti-Xa activity under a therapeutic dose of heparin. Int J Hematol. 2015; 101: 119-25.

[22] Wei MY, Ward SM. The anti-factor Xa range for low molecular weight heparin thromboprophylaxis. Hematol Rep. 2015; 7: 5844.

[23] Tahaineh L, Edaily SM, Gharaibeh SF. Anti-factor Xa levels in obese patients receiving enoxaparin for treatment and prophylaxis indications. Clin Pharmacol Adv Appl. 2018; 10: 63-70.

[24] Ellis RJ, Cunningham MT, Cook JD, Purdue GF, Hunt JL, Rue LW, et al. Laboratory heparin resistance in burn injury complicated by venous thrombosis. Burns. 1999; 25: 749-52.

[25] Lin H, Faraklas I, Saffle J, Cochran A. Enoxaparin dose adjustment is associated with low incidence of venous thromboembolic events in acute burn patients. J Trauma Inj Infect Crit Care. 2011; 71: 1557-61.

[26] Wahl WL, Brandt MM, Ahrns KS, Zajkowski PJ, Proctor MC, Wakefield TW, et al. Venous thrombosis incidence in burn patients: preliminary results of a prospective study. J Burn Care Rehabil. 2002; 23(2): 97-102.

[27] Junqueira DR, Perini E, Penholati RR, Carvalho MG. Unfractionated heparin versus low molecular weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patients. Cochrane Database Syst Rev. 2017; 4(4): CD007557.

[28] Walenga JM, Jeske WP, Margaret Prechel M, Bacher P, Bakhos M. Decreased prevalence of heparin-induced thrombocytopenia with low-molecular-weight heparin and related drugs. Semin Thromb Hemost. 2004; 30(suppl 1): 69-80.

[29] Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood. 2005; 106: 2710-5.

[30] Olson ST, Chuang Y-J. Heparin activates antithrombin anticoagulant function by generating new interaction sites (exosites) for blood clotting proteinases. Trends Cardiovasc Med. 2002; 12: 331-8.

[31] Herbert J-M, Petitou M, Hérault J-P, Bernat A, Driguez P-A, Duchaussoy P, et al. Synthesis of thrombin-inhibiting heparin mimetics without side effects. Nature. 1999; 398: 417-22.

[32] Weitz JI. Low-molecular-weight heparins. N Engl J Med. 1997; 337: 688-99.

[33] Lavrentieva A, Kontakiotis T, Bitzani M, Parlapani A, Thomareis O, Scourtis H, et al. The efficacy of antithrombin administration in the acute phase of burn injury. Thromb Haemost. 2008; 100: 286-90.

[34] Danielsson P, Nilsson L, Nettelblad H, Sjöberg F. Is there a need for antithrombin III substitution early after burn injury? Burns. 1997; 23: 300-5.

[35] Niedermayr M, Schramm W, Kamolz L, Andel D, Römer W, Hoerauf K, et al. Antithrombin deficiency and its relationship to severe burns. Burns. 2007; 33: 173-8.

[36] Lehninger AL, Nelson DL, Cox MM. Lehninger Principles of Biochemistry. New York: W. H. Freeman, 2005.

[37] Peeters H.Protides of the Biological Fluids: Proceedings of the Eighteenth Colloquium, Bruges, 1970. Amsterdam: Elsevier Science, 2013.

[38] Longstaff C, Hogwood J, Gray E, Komorowicz E, Varjú I, Varga Z, et al. Neutralisation of the anti-coagulant effects of heparin by histones in blood plasma and purified systems. Thromb Haemost. 2015; 115: 591-9.

[39] Iba T, Hashiguchi N, Nagaoka I, Tabe Y, Kadota K, Sato K. Heparins attenuated histone-mediated cytotoxicity in vitro and improved the survival in a rat model of histone-induced organ dysfunction. Intensive Care Med Exp. 2015; 3: 36.

[40] Hogwood J, Pitchford S, Mulloy B, Page C, Gray E. Heparin and non-anticoagulant heparin attenuate histone-induced inflammatory responses in whole blood. PLoS One. 2020; 15: e0233644. https://doi.org/10.1371/journal.pone.0233644.

[41] Zarychanski R, Abou-Setta A, Kanji S, Turgeon A, Kumar A, Houston D, et al. Efficacy and safety of heparin in patients with sepsis: a systematic review and meta-analysis. Crit Care. 2015; 19: P123.

[42] Wang C, Chi C, Guo L, Wang X, Guo L, Sun J, et al. Heparin therapy reduces 28-day mortality in adult severe sepsis patients: a systematic review and meta-analysis. Crit Care. 2014; 18: 563.

[43] Morita S, Gebska MA, Kakkar AK, Scully MF. High affinity binding of heparin by necrotic tumour cells neutralises anticoagulant activity-implications for cancer related thromboembolism and heparin therapy. Thromb Haemost. 2001; 86: 616-22.

[44] Ammollo CT, Semeraro N, Carratù MR, Colucci M, Semeraro F. Histones differentially modulate the anticoagulant and profibrinolytic activities of heparin, heparin derivatives, and dabigatran. J Pharmacol Exp Ther. 2016; 356(2): 305-13.

[45] Esmon CT. Molecular circuits in thrombosis and inflammation. Thromb Haemost. 2013; 109: 416-20.

[46] Aslam MS, Sundberg S, Sabri MN, Cooke D, Lakier JB. Pharmacokinetics of intravenous/subcutaneous enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. Catheter Cardiovasc Interv. 2002; 57: 187-90.

[47] Fareed J, Hoppensteadt D, Walenga J, Iqbal O, Ma Q, Jeske W, et al. Pharmacodynamic and pharmacokinetic properties of enoxaparin. Clin Pharmacokinet. 2003; 42: 1043-57.

[48] Azizi M, Veyssier-Belot C, Alhenc-Gelas M, Chatellier G, Billaud-Mesguish E, Fiessinger JN, et al. Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers. Br J Clin Pharmacol. 1995; 40: 577-84.

[49] Blake M, Roadley-Battin R, Torlinski T. Prophylactic anticoagulation after severe burn injury in critical care settings. Acta Med Litu. 2019; 26: 38-45.

[50] Barrowcliffe TW, Curtis AD, Johnson EA, Thomas DP. An international standard for low molecular weight heparin. Thromb Haemost. 1988; 60: 1-7.

[51] Siemens Healthineers.Sysmex CS-2000i/CS-2100i Systems. https://www.siemens-healthineers.com/hemostasis/systems/sysmex-cs-2000i. Accessed 23 Feb 2020.

[52] Martin-Toutain I, Jobic L, Mancic T, Ankri A. Évaluation de l’automate d’hémostase Sysmex^® CS-2100i (Siemens) pour les tests TCA, TP, fibrinogène, facteurs V et VIII, antithrombine et D-dimères. Ann Biol Clin (Paris). 2011; 69: 699-704.

[53] R Core Team (2016). In: R: A Language and Environment for Statistical Computing, 2013.

[54] Wickham H.ggplot2: Elegant Graphics for Data Analysis. New York: Springer, 2009.

[55] Kassambara A.ggpubr: “ggplot2” Based Publication Ready Plots, 2020.

[56] Yoshida K, Bartel A. Tableone: Create “Table 1” to Describe Baseline Characteristics with or without Propensity Score Weights, 2020.

[57] Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed-effects models using Ime4. J Stat Softw. 2015; 67: 1-48.

[58] Eager CD. standardize: Tools for Standardizing Variables for Regression in R, 2017.

[59] Levine MN, Planes A, Hirsh J, Goodyear M, Vochelle N, Gent M. The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparine low molecular weight heparin to prevent deep vein thrombosis after hip replacement. Thromb Haemost. 1989; 62: 940-4.

[60] Ekaney ML, Otto GP, Sossdorf M, Sponholz C, Boehringer M, Loesche W, et al. Impact of plasma histones in human sepsis and their contribution to cellular injury and inflammation. Crit Care. 2014; 18: 543.

[61] Hirose T, Hamaguchi S, Matsumoto N, Irisawa T, Seki M, Tasaki O, et al. Presence of neutrophil extracellular traps and citrullinated histone H3 in the bloodstream of critically ill patients. PLoS One. 2014; 9: e111755. https://doi.org/10.1371/journal.pone.0111755.

[62] Wildhagen KCAA, García De Frutos P, Reutelingsperger CP, Schrijver R, Ares C, Ortega-Omez A, et al. Nonanti-coagulant heparin prevents histone-mediated cytotoxicity in vitro and improves survival in sepsis. Blood. 2014; 123: 1098-101.

[63] Meara CHO, Coupland LA, Kordbacheh F, Quah BJC, Chang C-W, Simon Davis DA, et al. Neutralizing the pathological effects of extracellular histones with small polyanions. Nat Commun. 2020; 11: 6408.

[64] Kolaczkowska E, Jenne CN, Surewaard BGJ, Thanabalasuriar A, Lee W-Y, Sanz M-J, et al. Molecular mechanisms of NET formation and degradation revealed by intravital imaging in the liver vasculature. Nat Commun. 2015; 6: 6673.

[65] Priglinger U, Delle Karth G, Geppert A, Joukhadar C, Graf S, Berger R, et al. Prophylactic anticoagulation with enoxaparin: is the subcutaneous route appropriate in the critically ill? Crit Care Med. 2003; 31: 1405-9.

[66] Haas CE, Nelsen JL, Raghavendran K, Mihalko W, Beres J, Ma Q, et al. Pharmacokinetics and pharmacodynamics of enoxaparin in multiple trauma patients. J Trauma. 2005; 59: 1336-43 discussion 1343-4.

[67] Bittner EA, Shank E, Woodson L, Martyn JAJ. Acute and perioperative care of the burn-injured patient. Anesthesiology. 2015; 122: 448-64.

[68] Boneu B, Caranobe C, Sie P. Pharmacokinetics of heparin and low molecular weight heparin. Baillières Clin Haematol. 1990; 3: 531-44.

[69] Guillet B, Simon N, Joseampol J, Lorec-Penet A-M, Portugal H, Berland Y, et al. Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis. Nephrol Dial Transplant. 2003; 18: 2348-53.

[70] Weinbren MJ. Pharmacokinetics of antibiotics in burn patients. J Antimicrob Chemother. 1999; 44: 319-27.

[71] Denton J, Lane DA, Thunberg L, Slater AM, Lindahl U. Binding of platelet factor 4 to heparin oligosaccharides. Biochem J. 1983; 209: 455-60.

[72] Levine SP, Sorenson RR, Harris MA, Knieriem LK. The effect of platelet factor 4 (PF4) on assays of plasma heparin. Br J Haematol. 1984; 57: 585-96.

[73] Baglin T, Barrowcliffe TW, Cohen A, Greaves M. Guidelines on the use and monitoring of heparin. Br J Haematol. 2006; 133: 19-34.